Research and Markets: Head and Neck Cancer Squamous Cell Carcinoma: Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development and Enlists All Their Major and Minor Projects

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/468j8r/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team.

Scope

• The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

Companies Mentioned

1. AbbVie Inc.
2. Acceleron Pharma, Inc.
3. Advaxis, Inc.
4. Altor BioScience Corporation
5. Amgen Inc.
6. Ascenta Therapeutics, Inc.
7. Astex Pharmaceuticals, Inc.
8. AstraZeneca Plc
9. AVEO Pharmaceuticals, Inc.
10. BIND Therapeutics, Inc.
11. Boehringer Ingelheim GmbH
12. Bristol-Myers Squibb Company
13. CEL-SCI Corporation
14. Celldex Therapeutics, Inc.
15. Celltrion, Inc.
16. Centrose Llc
17. Critical Outcome Technologies Inc.
18. Daiichi Sankyo Company, Limited
19. Eisai Co., Ltd.
20. Eli Lilly and Company
21. F. Hoffmann-La Roche Ltd.
22. Genentech, Inc.
23. Genexine, Inc.
24. GlaxoSmithKline Plc
25. Gliknik, Inc.
26. Glycotope GmbH
27. ImmunoGen, Inc.
28. Immunomedics, Inc.
29. Immunovative Therapies, Ltd.
30. Incyte Corporation
31. Innate Pharma SA
32. Inovio Pharmaceuticals, Inc.
33. Karyopharm Therapeutics, Inc.
34. Laboratoires Pierre Fabre SA
    

For more information visit http://www.researchandmarkets.com/research/468j8r/head_and_neck.